MTVA - MetaVia Inc. Common Stock
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 1.02 0.01 (1.04%) | --- | --- | 0.0 (0.0%) | -0.01 (-0.98%) | 0.08 (7.92%) | -0.04 (-3.68%) | -0.04 (-3.68%) |
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
Category:
PHARMACEUTICAL PREPARATIONS
Market Period:
Closed
Earnings & Ratios
- Basic EPS:
- -0.26
- Diluted EPS:
- -0.26
- Basic P/E:
- -3.9638
- Diluted P/E:
- -3.9638
- RSI(14) 1m:
- 0.0
- VWAP:
- 1.03
- RVol:
- 0.0216
Events
| Period | Kind | Movement | Occurred At |
|---|---|---|---|
| 1m | Price increase 1m | 1.09 +0.03 (+2.35%) | Oct 15 15:59 |
| 1m | Price increase 1m | 1.07 +0.02 (+1.9%) | Oct 15 15:36 |
| 1m | Price increase 1m | 1.03 +0.02 (+1.99%) | Oct 15 11:09 |